HUMAW
MaterialsHumacyte Inc - Warrants (27/08/2026)
Live · NASDAQ · May 9, Close
What's Moving HUMAW Today?
No stock-specific AI insight has been generated for HUMAW yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.08
Fundamentals
Trading
HUMAW News
20 articles- Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's WhyYahoo Finance·May 8, 2026
- Humacyte To Announce 2026 First Quarter Financial Results and Provide Business Update on May 13, 2026Yahoo Finance·May 8, 2026
- A Look At Fresenius Medical Care (XTRA:FME) Valuation After The Symvess Distribution Agreement RevisionYahoo Finance·May 3, 2026
- Fresenius Medical Care’s Symvess Deal Shift And What It Means For ValuationYahoo Finance·May 3, 2026
- Humacyte, Inc. (HUMA) Surpasses Market Returns: Some Facts Worth KnowingYahoo Finance·Apr 30, 2026
- Humacyte Highlights Dialysis Access Data; Women Show Strong ATEV Edge, V012 Results Due in JuneMarketbeat·Apr 29, 2026
- Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026Yahoo Finance·Apr 27, 2026
- Humacyte Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess®Yahoo Finance·Apr 24, 2026
- Humacyte Appoints Jim Mercadante as Chief Commercial OfficerYahoo Finance·Apr 22, 2026
- Humacyte Announces Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess® for Vascular Trauma RepairYahoo Finance·Apr 21, 2026
- Frontier Bio Wins 'Best Paper' at 50th Annual VESS Meeting for Single-Surgery Regenerative Vascular GraftYahoo Finance·Apr 9, 2026
- Humacyte, Inc. (HUMA) Stock Declines While Market Improves: Some Information for InvestorsYahoo Finance·Apr 7, 2026
- Why BTIG Cut Its Target on Humacyte (HUMA) but Kept a Bullish View on the Bigger OpportunityYahoo Finance·Mar 29, 2026
- Humacyte Q4 Earnings Call HighlightsMarketbeat·Mar 27, 2026
- Humacyte, Inc. (HUMA) Reports Q4 Loss, Misses Revenue EstimatesYahoo Finance·Mar 27, 2026
- Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business UpdateGlobeNewswire Inc.·Mar 27, 2026
- Humacyte Appoints Rick McElheny as Senior Vice President of Business DevelopmentYahoo Finance·Mar 26, 2026
- Is Humacyte (HUMA) Using Middle East Partnerships To Reframe Its Capital and Market Access Strategy?Yahoo Finance·Mar 24, 2026
- Wall Street Analysts Think Humacyte, Inc. (HUMA) Is a Good Investment: Is It?Yahoo Finance·Mar 23, 2026
- Humacyte To Announce 2025 Fourth Quarter and Year End Financial Results and Provide Business Update on March 27, 2026Yahoo Finance·Mar 23, 2026
All 20 articles loaded
Price Data
52-Week Range
$0.08
Fundamentals
Trading
About Humacyte Inc - Warrants (27/08/2026)
Humacyte Inc. is an innovative biotechnology firm dedicated to developing and commercializing universally implantable human tissues, with a particular emphasis on its groundbreaking human acellular vessel (HAV) technology. The company is at the forefront of transforming vascular and regenerative medicine, leveraging its advanced manufacturing capabilities and robust clinical trial progress to address significant healthcare challenges. Humacyte's strategic focus on improving patient outcomes and its pipeline of transformative tissue-based solutions position it favorably for impactful partnerships and accelerated growth within the regenerative medicine market. By aligning with urgent medical needs, Humacyte is set to make a significant contribution to the future of healthcare.